Interactions Between Endothelial Mediators
Ryszard J. Gryglewski
Institute of Pharmacology, Medical College of Jagiellonian University, 16 Grzegórzecka, PL-31-531 Cracow, Poland
Search for more papers by this authorRyszard J. Gryglewski
Institute of Pharmacology, Medical College of Jagiellonian University, 16 Grzegórzecka, PL-31-531 Cracow, Poland
Search for more papers by this authorAbstract
Abstract Prostacyclin, nitric oxide and tissue plasminogen activator constitute a prominent triad of endothelial mediators. Prostacyclin is responsible mainly for maintaining vascular thromboresistance against platelet clumps, inhibits proliferation of vascular smooth muscle and modulates cholesterol turnover, tissue plasminogen activator is a fibrinolytic agent and nitric oxide controls vascular tone and structure. Receptor agonists such as acetylcholine, kinins, endothelins or adenosine diphosphate evoke a coupled release of mediators from endothelial cells. Prostacyclin and nitric oxide synergize in their antiplatelet, fibrinolytic and cardioprotective, but not in their hypotensive actions. Prostacyclin, but not nitric oxide, prevents paradox thrombogenic effects of tissue plasminogen activator. Filogenetically, prostacyclin and tissue plasminogen activator are younger brothers of nitric oxide from which they take over and perfect regulatory properties in circulation. Further studies on interactions of endothelial mediators may lead to a better understanding of mechanisms of thrombosis, atherogenesis, diabetic angiopathies, endotoxic shock and arterial hypertension.
References
- Aoyama, T., Y. Yui, H. Morishita & C. Kawai: Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in myocardial infarction and unstable angina pectoris. Circulation 1990, 81, 1784–1791.
- Basista, M., L. Grodzinska & J. Święs: The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation. Thromb. Haemostas. 1985, 54, 746–749.
- Bieroń, K., L. Grodzinska, E. Kostka-Trąbka & R. J. Gryglewski: Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease. Wien. Klin. Wochenschr. 1993, 105, 7–11.
- Bowen, R. & R. J. Haslam: Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role of cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1. J. Cardiovasc. Pharmacol. 1991, 17, 424–433.
- Casino, P. R., C. M. Kilcoyne, A. A. Quyyumi, J. M. Hoeg & J. A. Panza: The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993, 88, 2541–2547.
- Cayatte, A. J., J. J. Palacino, K. Horten & R. A. Cohen: Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb. 1994, 14, 753–759.
- Chester, A. H., G. O'Neal, S. Moncada, S. Tadjkarimi & M. H. Yacoub: Low basal and stimulated level of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 1990, 336, 897–900.
- Chin, J. H., S. Azhar & B. B. Hoffman: Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J. Clin. Invest. 1992, 89, 10–18.
- Chłopicki, S. & R. J. Gryglewski: Nitric oxide is a major mediator in reactive hyperaemia evoked by a brief coronary occlusion in the guinea pig heart. Eur. J. Pharmacol. 1993, 241, 117–120.
- Chowienczyk, P. J., G. F. Watts, J. R. Cockroft & J. M. Ritter: Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992, 340, 1430.
- Cockroft, J. R., P. J. Chowienczyk, N. Benjamin & J. M. Ritter: Preserved endothelium-dependent vasodilatation in patients with essential hypertension. New Engl. J. Med. 1994, 330, 1036–1040.
- Cooke, J. P. & P. S. Tsao: Is NO an endogenous antiatherogenic molecule Atheroscler. Thromb. 1994, 14, 653–655.
- Cooke, J. P., A. H. Singer, P. Tsao, P. Zera, R. A. Rowan & M. E. Billingham: Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 1992, 90, 1168–1172.
- Corbett, J. A., G. Kwon, J. Turk & M. L. McDaniel: IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry 1993, 32, 13767–13770.
- Cosentino, F., J. C. Sill & Z. S. Katusić: Role of superoxide anions in the mediation of endothelium-dependent contractions. Hypertension 1994, 23, 229–235.
- Creager, M. A., S. J. Gallagher, J. Girerd, S. M. Coleman, V. J. Dzau & J. P. Cooke: L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. 1992, 90, 1248–1253.
- Dembińska-Kieć, A., E. Kostka-Trąbka & R. J. Gryglewski: Effect of prostacyclin on fibrinolytic activity in patients with arterio sclerosis obliterans. Thromb. Haemostas. 1982, 42, 190–???.
- De Nucci, G., R. J. Gryglewski, T. D. Warner & J. R. Vane: Receptor mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc. Natl. Acad. Sci. USA 1988, 85, 2334–2338.
- Doni, M. G., B. J. R. Whittle, R. M. J. Palmer & S. Moncada: Actions of nitric oxide on the release of prostacyclin from bovine endothelial cells in culture. Eur. J. Pharmacol. 1988, 151, 19–25.
- Drexler, H., A. M. Zeicher, K. Meinzer & H. Just: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991, 338, 1546–1550.
- Dubois-Randé, J. L., R. Zelinsky, F. Roudot, P. E. Chabrier, A. Castaigne, H. Geschwind & S. Adnot: Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Amer. J. Cardiol. 1992, 70, 1269–1275.
- Durante, W., A. K. Sen & F. A. Sunahara: Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Brit. J. Pharmacol. 1988, 94, 463–468.
- Feelisch, M.: The biochemical pathways of nitric oxide formation from nitrovasodilators: appriopriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J. Cardiovasc. Pharmacol. 1991, 17, S25–S33.
- Fitzgerald, D. J., F. Catella, M. D. Louis Roy & G. A. Fitzgerald: Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988, 77, 142–150.
- Fitzgerald, G. A., B. Smith, A. K. Pedersen & A. R. Brash: Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. New Engl. J. Med. 1984, 310, 1060–1065.
- Flavahan, N. A.: Atherosclerosis or lipoprotein-induced endothelial dysfunction. Circulation 1992, 85, 1927–1938.
- Franchi, A. M., M. Chaud, V. Rettori, A. Suburo, S. M. McCann & M. Gimeno: Role of nitric oxide in eicosanoid synthesis and uterine motility in estrogen-treated rat uteri. Proc. Natl. Acad. Sci. USA 1994, 91, 539–543.
- Furlong, B., A. H. Henderson, M. J. Lewis & J. A. Smith: Endothelium-derived relaxing factor inhibitis in vitro platelet aggregation. Brit. J. Pharmacol. 1987, 90, 687–692.
- Galle, J., A. Mülsch, R. Busse & E. Bassenge: Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor. Arterioscler. Thromb. 1991, 11, 198–203.
- Gillard, T., A. Mulsch, H. Klein & K. Decker: Regulation by prostaglandin E2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages. Biol. Chem. Hoppe-Seyler 1992, 373, 897–902.
- Gilligan, D. M., V. Guetta, J. A. Panza, C. E. Garcia, A. A. Quyyumi & R. O. Cannon: Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994, 90, 35–41.
- Griscavage, J. M., N. E. Rogers, M. P. Sherman & L. J. Ignarro: Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. J. Immunol. 1993, 151, 6329–6337.
- Grodzińska, L., G. Hafner & H. Darius: Effect of molsidomine on t-PA and PAI activity in man: a double blind, placebo controlled study. Thromb. Haemostas. 1990, 64, 485–???.
- Gryglewski, R. J.: Nitric oxide and atherosclerosis. Thromb. Haemorrh. Disorders 1990, 2, 1–9.
- Gryglewski, R. J.: Interactions between nitric oxide and prostacyclin. Semin. Thromb. Haemostas. 1993, 19, 158–166.
- Gryglewski, R. J. & J. Święs: Streptokinase - prostacyclin - nitric oxide: in vivo interactions. In: Adv. Prostagl. Thromb. Leukotr. Res. Vol. 23, Ed. B. Samuelsson et al., Raven Press New York 1995, pp. 479–484.
- Gryglewski, R. J., R. M. Botting & J. R. Vane: Mediators produced by the endothelial cell. Hypertension 1988, 12, 530–548.
- Gryglewski, R. J., S. Bunting, S. Moncada, R. J. Flower & J. R. Vane: Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 1976, 12, 685–713.
- Gryglewski, R. J., S. Chłopicki, J. Święs & P. Niezabitowski: Prostacyclin, nitric oxide and atherosclerosis. In: Atherosclerosis III: Recent advances in atherosclerosis research. Eds. F. Numano & R. W. Wissler, Ann. NY Acad. Sci. 1995, Vol. 748, pp. 194–207.
- Gryglewski, R. J., A. Dembińska-Kieć, A. Żmuda & T. Gryglewska: Prostacyclin and thromboxane A2 biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 1978a, 31, 385–394.
- Gryglewski, R. J., R. Korbut, A. Ocetkiewicz & J. Stachura: In vivo method for quantitation of anti-platelet potency of drugs. Naunyn-Schmiedeberg's Arch. Pharmacol. 1978b, 302, 25–30.
- Gryglewski, R. J., R. Korbut, E. Trąbka-Janik, A. Zembowicz & M. Trybulec: Interaction between NO donors and iloprost in human vascular smooth muscle, platelets and leukocytes. J. Cardiovasc. Pharmacol. 1989, 14, S124–S128.
- Gryglewski, R. J., S. Moncada & R. M. J. Palmer: Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Brit. J. Pharmacol. 1986a, 87, 685–694.
- Gryglewski, R. J., R. M. J. Palmer & S. Moncada: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986b, 320, 454–456.
- Gryglewski, R. J., J. Święs, S. Chłopicki & P. Niezabitowski: Permissive effect of molsidomine towards cardioprotective action of iloprost in myocardial ischaemia in cats. J. Physiol. Pharmacol. 1993, 44, 313–318.
- Gryglewski, R. J., A. Zembowicz, D. Salvemini, G. W. Taylor & J. R. Vane: Modulation of the pharmacological actions of nitro-vasodilators by methylene blue and pyocyanin. Brit. J. Pharmacol. 1992, 106, 838–845.
- Hatchett, R. J., R. J. Gryglewski, J. Młochowski, A. Zembowicz & W. Radziszewski: Carboxyebselen - a potent and selecive inhibitor of endothelial nitric oxide synthase. J. Physiol. Pharmacol. 1994, 45, 55–67.
- Hogg, N., B. Kalyanaraman, J. Joseph, A. Struck & S. Parthasarathy: Inhibition of low density lipoprotein oxidation by nitroc oxide. FEBS 1993, 334, 170–174.
- Imai, Y., H. Kolb & V. Burkart: Nitric oxide production from macrophages is regulated by arachidonic acid metabolites. Biochem. Biophys. Res. Commun. 1993, 197, 105–109.
- Inoue, T., M. Shigeto, E. Koh & T. Ogihara: Nitric oxide mediates interleukin-1 prostaglanding E2 production by vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 1993, 194, 105–109.
- Kanner, J., S. Harel & R. Granit: Nitric oxide, an inhibitor of lipid oxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids 1992, 27, 46–49.
- Kaplan, K. L., T. Mather, L. De Marco & S. Solomon: Effect of fibrin on endothelial cell production of prostacyclin and tissue plasminogen activator. Atherosclerosis 1989, 9, 43–49.
- Keen, M., S. A. W. Pickering & J. A. Hunt: Modulation of bradykinin-stimulated release of prostacyclin from endothelial cells. Brit. J. Pharmacol. 1990, 101, 524P.
- Korbut, R., K. Bieroń & R. J. Gryglewski: Effect of L-arginine on plasminogen activator inhibitor in hypertensive patients with hypercholesterolaemia. New Engl. J. Med. 1993, 328, 287–288.
- Korbut, R., P. S. Lidbury & J. R. Vane: Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators. Lancet 1990, 335, 669–???.
- Kuhn, M., A. Otten, C. Jürgen, C. Frölich & V. Försterman: Endothelial cyclic GMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor/nitric oxide from bovine aortic endothelial cells. J. Pharmacol. Exp. Therap. 1991, 256, 677–682.
- Leung, W.-H., Ch.-P. Lau & Ch.-K. Wong: Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993, 341, 1496.
- Lidbury, P. S., E. Antunes, G. De Nucci & J. R. Vane: Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation. Brit. J. Pharmacol. 1989, 98, 1275–1280.
- Lidbury, P. S., Ch. Thiemermann, R. Korbut & J. R. Vane: Endothelins release tissue plasminogen activator and prostanoids. Eur. J. Pharmacol. 1990, 186, 205–212.
- Linder, L., F. R. Kiowski, F. R. Bühler & T. F. Lüscher: Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990, 81, 1762–1767.
- Loosemore, T. M., T. C. Chalmers & J. A. Dormandy: A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int. Angiol. 1994, 13, 133–142.
- Lugnier, C. & N. Komas: Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur. Heart J. 1993, 14, Suppl. 1, 141–148.
- Lüscher, T. F.: The endothelium and cardiovascular disease - a complex relation. New Engl. J. Med. 1994, 330, 1081–1083.
- Marotta, P., L. Sautebin & M. Di Rosa: Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line J774 cells. Brit. J. Pharmacol. 1992, 107, 640–641.
- Mayer, B., F. Brunner & K. Schmidt: Novel actions of methylene blue. Eur. Heart J. 1993, 14, suppl. 1, 22–26.
- Mayhan, W. G.: Impairement of endothelium-dependent dilatation of the basilar artery during diabetes mellitus. Brain Res. 1992, 580, 297–302.
- Mehta, J. L., D. Lawson, P. Mehta & T. Saldeen: Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. Proc. Natl. Acad. Sci. USA 1988, 85, 4511–4516.
- Minor, R. L. Jr., P. R. Myers, R. Guerra, Jr., Y. N. Bates & D. G. Harrison: Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J. Clin. Invest. 1990, 86, 2109–2116.
- Mitchell, J. A., P. Akarasereenont, C. Thiemermann, R. J. Flower & J. R. Vane: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 1994, 90, 11693–11697.
- Mitchell, J. A., T. A. Świerkosz, T. D. Warner, S. Gross, C. Thiemermann & J. R. Vane: Regulation of prostacyclin synthesis by the release of endogenous nitric oxide in response to lipopolysaccharide. Brit. J. Pharmacol. 1993, 109, 4P.
- Morishita, H., Y. Yui, R. Hattori, T. Aoyama & C. Kawai: Increased hydrolysis of cholesteryl ester with prostacyclin is potentiated by high density lipoprotein through the prostacyclic stabilization. J. Clin. Invest. 1990, 86, 1885–1891.
- Musiał, J., M. Wilczyńska, K. Sładek, C. S. Cierniewski, R. Niżankowski & A. Szczeklik: Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986, 31, 61–70.
- Naruse, K., K. Shimizu, M. Muramatsu, Y. Toki, Y. Miyazaki, K. Okumura, H. Hashimoto & T. Ito: Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. Arterioscler. Thromb. 1994, 14, 746–752.
- Nicolini, F. A. & J. L. Mehta: Iloprost and tissue-type plasminogen activator differentially affect platelet aggregation in platelet-rich plasma and in whole blood. Thromb. Res. 1990, 60, 337–342.
- Nolte, C., M. Eigenthalter, P. Schanzenbacher & V. Walters: Endothelial cell-dependent phosphorylation of a platelet protein mediated by c-AMP and c-GMP elevating factors. J. Biol. Chem. 1991, 266, 14808–14812.
- Ohgushi, M., K. Kugiyama, K. Fukunaga, T. Murohara, S. Sugiyama, E. Miyamoto & H. Yasue: Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arterioscler. Thromb. 1993, 13, 1525–1532.
- Panza, J. A., P. R. Casino, D. M. Badar & A. A. Quyyumi: Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993, 87, 1475–1481.
- Peto, J., K. Mihai & A. Makary: Low level of prostacyclin as a risk of ischaemic heart disease. Int. J. Cardiol. 1991, 30, 237–239.
- Plane, F., M. Jacobs, D. McManus & K. R. Bruckdorfer: Probucol and other antioxidants prevent the inhibition of endothelium-dependent relaxation by low density lipoproteins. Atherosclerosis 1993, 103, 73–79.
- Pomerantz, K. B. & D. P. Hajjar: High-density lipoprotein-induced cholesterol efflux from arterial smooth muscle cell derived foam cells: functional relationship of the cholesterol ester cycle and eicosanoid biosynthesis. Biochemistry 1990, 29, 1892–1899.
- Radomski, M. W., R. M. J. Palmer & S. Moncada: The anti-aggregatory properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Brit. J. Pharmacol. 1987a, 92, 639–646.
- Radomski, M. W., R. M. J. Palmer & S. Moncada: Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Brit. J. Pharmacol. 1987b, 92, 181–187.
- Rettori, V., M. Gimeno, K. Lyson & S. M. McCann: Nitric oxide mediates norepinephrine-induced prostaglandin E2-release from the hypothalamus. Proc. Natl. Acad. Sci. USA 1992, 89, 11543–11546.
- Rimarachin, J. A., J. A. Jacobson, P. Szabo, J. Maclouf, C. Creminon & B. B. Weksler: Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler. Thromb. 1994, 14, 1021–1031.
- Rossitch, E., E. Alexander III, P. Mc L. Black & J. P. Cooke: L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J. Clin. Invest. 1991, 87, 1295–1299.
-
Rubanyi, G. M.: Reversal of hypercholesterolemia-induced endothelial dysfunction by L-arginine.
Circulation
1991, 83, 118–120.
10.1161/01.CIR.83.3.1118 Google Scholar
- Salvemini, D., T. P. Misko, J. L. Masferrer, K. Seibert, M. G. Currie & P. Needleman: Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA 1993, 90, 7240–7244.
- Schafer, A. I., G. B. Zavoico, J. Loscalzo & A. K. Mass: Synergistic inhibition of platelet activation by plasmin and prostaglandin I2. Blood 1987, 69, 1504–1507.
- Schmidt, K., W. F. Graier, G. M. Kostner, B. Mayer, E. Böhme & W. R. Kukovetz: Stimulation of soluble guanylate cyclase by endothelium-derived relaxing factor is antagonized by oxidized low-density lipoprotein. J. Cardiovasc. Pharmacol. 1991, 17, Suppl 3, S83–S88.
- Schott, C. A., C. M. Bogen, P. Vetrovsky, C. C. Berton & J.-C. Stoclet: Exogenous NG-hydroxy-L-arginine causes nitrite production in vascular smooth muscle cells in the absence of nitric oxide synthase activity. FEBS Lett. 1994, 341, 203–207.
- Sessa, W. C., J. K. Harrison, C. M. Barber, D. Zeng, M. E. Dureux, D. D. Angelo, K. R. Lynch & M. J. Peach: Molecular cloning and expression of cDNA encoding endothelial cells nitric oxide synthase. J. Biol. Chem. 1992, 267, 15274–15276.
- Simon, B. C., Ch. C. Haudenschild & R. A. Cohen: Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol. J. Cardiovasc. Pharmacol. 1993, 21, 893–901.
- Sinzinger, H., P. Fitscha, J. O'Grady, F. Rauscha, W. Rogati & J. R. Vane: Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease. Lancet 1990, 335, 627–628.
- Sinzinger, H., I. Virgolini, G. Lupatelli, E. Molinari, A. Gerakakis & P. Angelberger: Prostaglandin E1 decreases the low-density lipoprotein entry into rabbit arterial wall. Brit. J. Pharmacol. 1991, 103, 1626–1628.
- Soothgate, K. & A. C. Newby: Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 1990, 82, 113–123.
- Stadler, J., B. G. Harbrecht, M. Di Silvio, R. D. Curran, M. L. Jordan, R. L. Simmons & T. R. Billiar: Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by Kupffer cells. Leukoc. Biol. 1993, 53, 165–172.
- Stadler, J. S., M. Stefanovic-Racic, T. R. Billiar, R. D. Curran, L. A. McIntyre, H. I. Georgescu, R. L. Simmons & C. H. Evans: Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharides. J. Immunol. 1991, 147, 3915–3920.
- Stamler, J. S., D. E. Vaughan & J. Loscalzo: Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1 and nitroglycerin. Circ. Res. 1989, 65, 796–804.
- Stoclet, J.-C., J. Fleming, G. Gray, G. Julou-Schaeffer, F. Schneider, C. A. Schott, C. Schott & J. R. Parratt: Nitric oxide and endotoxaemia. Circulation 1993, 87, suppl. 5, 77–80.
- Szczeklik, A. & R. J. Gryglewski: Low-density lipoproteins (LDL) are carriers for lipid peroxides and invalidate prostacyclin (PGI2) biosynthesis in arteries. Arterty 1980, 7, 488–???.
- Świerkosz, T. A., J. A. Mitchell & T. A. Tomlinson: Relationship between different isoforms of nitric oxide synthase and cyclooxygenase in various cell types. Pol. J. Pharmacol. 1994, 46, 587–592.
- Taddei, S., A. Viridis, P. Mattei & A. Salvetti: Vasodilatation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993, 21, 929–933.
- Taguchi, J., J. Abe, H. Okazaki, Y. Takuwa & K. Kurokawa: L-Arginine inhibits neointimal formation following balloon injury. Life Sci. 1993, 53, 387–392.
- Thiemermann, C., C. Szabo, J. A. Mitchell & J. R. Vane: Vascular hyporeactivity to vasoconstrictor agents and haemodynamic decompensation in haemorrhagic shock is mediated by nitric oxide. Proc. Natl. Acad. Sci. USA 1993, 90, 267–271.
- Tokunaga, O., T. Yamada, J. L. Fan & T. Watanabe: Age-related decline in prostacyclin synthesis by human aortic endothelial cells. Quanlitative and quantitative analysis. Amer. J. Pathol. 1991, 138, 941–949.
- Topol, E. Y., S. G. Ellis, R. M. Califf, B. S. George, D. C. Stump, E. R. Nabel, J. A. Walton, R. J. Candella & K. L. Lee: Combined tissue-plasminogen activator and prostacyclin therapy for acute myocardial infarction. J. Amer. Coll. Cardiol. 1989, 14, 877–884.
- Tsai, A.-I.: How does NO activate hemeproteins FEBS Letter 1994, 341, 141–145.
- Valance, P., A. Leone, A. Calver, J. Collier & S. Moncada: Identification of an inhibitor of NO synthase in human plasma and urine. J. Vasc. Res. 1992, 29, 217–218.
- Vane, J. R. & R. M. Botting: Impact of risk factors on the endothelium. Cardiovasc. Risk. Factors 1994, 4, 108–121.
- Vane, J. R., J. A. Mitchell, I. Appleton, A. Tomlinson, D. Bishop-Bailey, J. Croxtall & D. A. Willoughby: Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc. Natl. Acad. Sci. USA 1994, 91, 2046–2050.
- Wang, T., P. Falardeau & W. S. Powell: Synthesis of prostaglandins and thromboxane B2 in cholesterol-fed rabbits. Arterioscler. Thromb. 1991, 11, 501–508.
- Willis, A. L. & D. L. Smith: Therapeutic impact of eicosanoids in atherosclerotic disease. Eicosanoids 1989, 2, 69–99.
- Witztum, J. L.: The oxidation hypothesis of atherosclerosis. Lancet 1994, 344, 793–795.
- Woditsch, I. & K. Schrör: Reduced endothelium-dependent relaxation at enhanced NO release in hearts of hypercholesterolaemic rabbits. Brit. J. Pharmacol. 1994, 111, 1035–1040.
- Yang, X., B. Cai, R. R. Sciacca & P. J. Cannon: Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ. Res. 1994, 74, 318–328.
- Zembowicz, A., R. J. Hatchett, W. Radziszewski & R. J. Gryglewski: Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thial essential for the catalytic activity of nitric oxide synthase. J. Pharmacol. Exp. Therap. 1993, 267, 1112–1118.